Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Exact Sciences Corporation

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) reported new trades on Friday, November 10, according to daily fund disclosures. ARK bought s...

Cathie Wood Loads Up on CoreWeave (CRWV), and Crypto Stocks; Trims Stakes in GitLab, AMD, and Other Tech Stocks

Analysts are intrested in these 5 stocks: ( ($NDAQ) ), ( ($IONQ) ), ( ($OPK) ), ( ($EXAS) ) and ( ($PANW) ). Here is a breakdown of their recent


Nasdaq, IonQ, Opko, Exact, Palo Alto: Trending by Analysts

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several notable portfolio adjustments on Thursday, November 20, as revealed in daily fun...

Cathie Wood Buys Nvidia, ACHR and Crypto Stocks, Offloads AMD, EXAS

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Exact Sciences (EXAS – Research Report) and Assembly...

Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Assembly Biosciences (ASMB)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Nano-X Imaging (NNOX – Research Report) and Exact Sc...

Analysts Are Bullish on These Healthcare Stocks: Nano-X Imaging (NNOX), Exact Sciences (EXAS)

Earnings reports, mergers, and other data are among the top stock market stories on Thursday.


Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!

Shares of Exact Sciences ($EXAS), the cancer screening and treatment provider, surged by about 18% on Thursday morning after it agreed to merge wit...

M&A News: Exact Sciences Stock (EXAS) Jumps 18% on Abbott’s $21B Acquisition

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mediwound (MDWD – Research Report) and Exact Science...

Analysts Are Bullish on Top Healthcare Stocks: Mediwound (MDWD), Exact Sciences (EXAS)

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several notable portfolio adjustments on Tuesday, November 11, as revealed in daily fund...

Cathie Wood Raises Bets on Alibaba and Baidu; Cuts RDDT, EXAS, and IRDM

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several notable portfolio adjustments on Thursday, November 6, according to daily fund d...

Cathie Wood Buys the Dip in Archer Aviation (ACHR) After Weak Q3 Results, Trims Stakes in Roku and TER Stocks

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Inspire Medical Systems (INSP – Research Report) and...

Analysts Offer Insights on Healthcare Companies: Inspire Medical Systems (INSP) and Exact Sciences (EXAS)

In a report released today, Michael Ryskin from Bank of America Securities reiterated a Buy rating on Exact Sciences, with a price target of $78.00...

Bank of America Securities Remains a Buy on Exact Sciences (EXAS)

In a report released today, Luke Sergott from Barclays maintained a Buy rating on Exact Sciences, with a price target of $77.00. The company’s shar...

Barclays Sticks to Its Buy Rating for Exact Sciences (EXAS)

Exact Sciences Corp ( ($EXAS) ) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its investors...

Exact Sciences Reports Record Q3 Revenue and Raises Guidance

In a report released today, Andrew Brackmann from William Blair maintained a Buy rating on Exact Sciences. The company’s shares opened today at $63...

William Blair Reaffirms Their Buy Rating on Exact Sciences (EXAS)

In a report released today, David Westenberg from Piper Sandler maintained a Buy rating on Exact Sciences, with a price target of $70.00. The compa...

Piper Sandler Sticks to Its Buy Rating for Exact Sciences (EXAS)

In a report released today, Kyle Mikson CFA from Canaccord Genuity maintained a Buy rating on Exact Sciences, with a price target of $46.91. The co...

Current Quarter	$0.18	Next Quarter	$0.14
Current Year	$0.43	Next Year	$1.4
QoQ Growth	-22.2%	YoY Growth	+225.6%
3Y EPS CAGR	-17.1%	Target Price	$82.95
Consensus	Buy	Upside	-17.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	EXAS	$100.90	+0.23%	19.18M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	EXAS	$100.90	+0.2%	19.18M
3
4
5
6

EXAS

EXAS

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Exact Sciences Corporation Data in Excel

Get Exact Sciences Corporation Data in Excel